Found 104 results
Type [ Year(Asc)]
M Gemberling, and CA Gersbach. "Boosting, Not Breaking: CRISPR Activators Treat Disease Models." Molecular Therapy 26, no. 2 (2018): 334-336.
AK Pickar, and CA Gersbach. "Gene therapies for hemophilia hit the mark in clinical trials." Nature Medicine 24, no. 2 (2018): 121-122.
GP Pathak, JI Spiltoir, C Höglund, LR Polstein, S Heine-Koskinen, CA Gersbach, J Rossi, and CL Tucker. "Bidirectional approaches for optogenetic regulation of gene expression in mammalian cells using Arabidopsis cryptochrome 2." Nucleic Acids Research 45, no. 20 (2017).
N Farhang, JM Brunger, JD Stover, PI Thakore, B Lawrence, F Guilak, CA Gersbach, LA Setton, and RD Bowles. "CRISPR-Based Epigenome Editing of Cytokine Receptors for the Promotion of Cell Survival and Tissue Deposition in Inflammatory Environments." Tissue Engineering, Part A 23, no. 15-16 (2017): 738-749.
TS Klann, JB Black, M Chellappan, A Safi, L Song, IB Hilton, GE Crawford, TE Reddy, and CA Gersbach. "CRISPR-Cas9 epigenome editing enables high-throughput screening for functional regulatory elements in the human genome." Nature Biotechnology 35, no. 6 (2017): 561-568.
LR Polstein, M Juhas, G Hanna, N Bursac, and CA Gersbach. "An Engineered Optogenetic Switch for Spatiotemporal Control of Gene Expression, Cell Differentiation, and Tissue Morphogenesis." ACS Synthetic Biology 6, no. 11 (2017): 2003-2013.
R Barrangou, and CA Gersbach. "Expanding the CRISPR Toolbox: Targeting RNA with Cas13b." Molecular Cell 65, no. 4 (2017): 582-584.
J Huang, M Chen, MJ Whitley, H-C Kuo, ES Xu, A Walens, YM Mowery, D Van Mater, WC Eward, DM Cardona et al. "Generation and comparison of CRISPR-Cas9 and Cre-mediated genetically engineered mouse models of sarcoma." Nature Communications 8 (2017).
CE Nelson, JN Robinson-Hamm, and CA Gersbach. "Genome engineering: a new approach to gene therapy for neuromuscular disorders." Nature Reviews Neurology 13, no. 11 (2017): 647-661.
SS Adkar, JM Brunger, VP Willard, C-L Wu, CA Gersbach, and F Guilak. "Genome Engineering for Personalized Arthritis Therapeutics." Trends in Molecular Medicine 23, no. 10 (2017): 917-931.
JM Brunger, A Zutshi, VP Willard, CA Gersbach, and F Guilak. "Genome Engineering of Stem Cells for Autonomously Regulated, Closed-Loop Delivery of Biologic Drugs." Stem Cell Reports 8, no. 5 (2017): 1202-1213.
D Manandhar, L Song, A Kabadi, JB Kwon, LE Edsall, M Ehrlich, K Tsumagari, CA Gersbach, GE Crawford, and R Gordân. "Incomplete MyoD-induced transdifferentiation is associated with chromatin remodeling deficiencies." Nucleic Acids Research 45, no. 20 (2017): 11684-11699.
JB Black, P Perez-Pinera, and CA Gersbach. "Mammalian Synthetic Biology: Engineering Biological Systems." Annual Review of Biomedical Engineering 19, no. 1 (2017): 249-277.
FT Moutos, KA Glass, SA Compton, AK Ross, CA Gersbach, F Guilak, and BT Estes. "Anatomically shaped tissue-engineered cartilage with tunable and inducible anticytokine delivery for biological joint resurfacing." Proceedings of the National Academy of Sciences of USA 113, no. 31 (2016): E4513-E4522.
CE Nelson, and CA Gersbach. "Cas9 loosens its grip on off-target sites." Nature Biotechnology 34, no. 3 (2016): 298-299.
JM Brunger, A Zutshi, VP Willard, CA Gersbach, and F Guilak. "CRISPR/Cas9 editing of induced pluripotent stem cells for engineering inflammation-resistant tissues." Arthritis and Rheumatology 69, no. 5 (2016): 1111-1121.
PI Thakore, and CA Gersbach. "Design, Assembly, and Characterization of TALE-Based Transcriptional Activators and Repressors." Methods in molecular biology (Clifton, N.J.) 1338 (2016): 71-88.
DG Ousterout, and CA Gersbach. "The Development of TALE Nucleases for Biotechnology." Methods in molecular biology (Clifton, N.J.) 1338 (2016): 27-42.
J Lee, L Xu, TM Gibson, CA Gersbach, and BA Sullenger. "Differential effects of toll-like receptor stimulation on mRNA-driven myogenic conversion of human and mouse fibroblasts." Biochemical and Biophysical Research Communications 478, no. 3 (2016): 1484-1490.
PI Thakore, JB Black, IB Hilton, and CA Gersbach. "Editing the epigenome: technologies for programmable transcription and epigenetic modulation." Nature Methods 13, no. 2 (2016): 127-137.
CE Nelson, and CA Gersbach. "Engineering Delivery Vehicles for Genome Editing." Annual Review of Chemical and Biomolecular Engineering 7, no. 1 (2016): 637-662.
JN Robinson-Hamm, and CA Gersbach. "Gene therapies that restore dystrophin expression for the treatment of Duchenne muscular dystrophy." Human Genetics 135, no. 9 (2016): 1029-1040.
IB Hilton, and CA Gersbach. "Genetic engineering: Chemical control for CRISPR editing." Nature Chemical Biology 13, no. 1 (2016): 2-3.
ML Maeder, and CA Gersbach. "Genome-editing Technologies for Gene and Cell Therapy." Molecular Therapy 24, no. 3 (2016): 430-446.
CE Nelson, CH Hakim, DG Ousterout, PI Thakore, EA Moreb, RM Castellano Rivera, S Madhavan, X Pan, FA Ran, WX Yan et al. "In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy." Science 351, no. 6271 (2016): 403-407.